CD309 (FLK1) Monoclonal Antibody (Avas12a1), Biotin, eBioscience™, Invitrogen™

Description

• Description: The Avas12a1 monoclonal antibody reacts with mouse Flk-1, also known as vascular endothelial growth factor receptor 2 (VEGFR2)
• Flk-1 is a receptor tyrosine kinase involved in vascular endothelial tissue development and is expressed on endothelial cells during embryonic stages and some endothelial tissues in the adult
• Applications Reported: The Avas12a1 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The Avas12a1 antibody has been tested by flow cytometric analysis of bEnd.3 cells
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Filtration: 0.2 μm post-manufacturing filtered
• KDR (FLK1, VEGFR2) is a type III receptor tyrosine kinase
• It binds vascular endothelial growth factor with high affinity in vitro, and is expressed early in development by endothelial cell precursors
• FLK1 (VEGF Receptor 2) encodes one of the two receptors of the VEGF
• This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase
• The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc
• Mutations of FLK1 (VEGF Receptor 2) are implicated in infantile capillary hemangiomas.